Citigroup Increases Biogen (NASDAQ:BIIB) Price Target to $215.00

Biogen (NASDAQ:BIIB) had its price objective raised by equities research analysts at Citigroup from $185.00 to $215.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. Citigroup’s target price points to a potential upside of 13.76% from the company’s current price.

Other equities analysts have also issued reports about the company. HC Wainwright upped their target price on Biogen from $194.00 to $228.00 and gave the stock a “buy” rating in a research report on Monday. HSBC restated a “reduce” rating and set a $143.00 price objective (down previously from $144.00) on shares of Biogen in a report on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Mizuho boosted their target price on shares of Biogen from $177.00 to $207.00 and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Finally, Tudor Pickering set a $201.00 price target on shares of Biogen in a research report on Monday. Thirteen investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $207.81.

Biogen Trading Down 2.5%

Shares of BIIB stock opened at $188.99 on Monday. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The stock has a 50 day simple moving average of $177.44 and a two-hundred day simple moving average of $157.89. The company has a market cap of $27.74 billion, a P/E ratio of 21.45, a PEG ratio of 1.55 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same period in the prior year, the business earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts forecast that Biogen will post 15.83 earnings per share for the current year.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at $1,607,232.69. This represents a 24.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.18% of the company’s stock.

Institutional Trading of Biogen

A number of large investors have recently added to or reduced their stakes in the stock. Norges Bank purchased a new position in Biogen in the fourth quarter valued at approximately $464,408,000. Orion Porfolio Solutions LLC lifted its position in shares of Biogen by 6,828.4% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after buying an additional 509,809 shares during the last quarter. Caisse de depot et placement du Quebec lifted its position in shares of Biogen by 718.2% during the 3rd quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company’s stock valued at $79,741,000 after buying an additional 499,676 shares during the last quarter. AQR Capital Management LLC increased its holdings in Biogen by 30.7% in the 3rd quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock worth $248,809,000 after acquiring an additional 418,776 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in Biogen by 190.7% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 624,371 shares of the biotechnology company’s stock valued at $78,415,000 after acquiring an additional 409,591 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and updated guidance — Biogen reported Q4 results and FY guidance that topped expectations (EPS and revenue beats; FY2026 EPS range of 15.25–16.25), a key driver for recent analyst upgrades and higher targets. Article Title
• Positive Sentiment: Leqembi subcutaneous BLA gets priority review — The biologics license application for a subcutaneous formulation of Leqembi (lecanemab) was designated for priority review, which could materially expand the Alzheimer’s franchise if approved. Article Title
• Positive Sentiment: Multiple bullish analyst moves lift upside — Several firms raised price targets and/or maintained Buy ratings after the results and pipeline updates (Goldman Sachs PT raised to $231; RBC to $233; HC Wainwright to $228; Canaccord and others also raised targets), supporting multi-quarter upside expectations. Article Title
• Neutral Sentiment: Pipeline diversification headlines (lupus, SMA) — Management and coverage note advancing programs beyond Alzheimer’s, which improves long-term growth optionality but will take time to materialize. Article Title
• Neutral Sentiment: Mixed analyst stances — Several shops raised price targets but kept neutral/hold ratings (Citigroup, Piper Sandler, Wedbush, Truist), indicating disagreement on valuation even after beats. Article Title
• Neutral Sentiment: Short-interest report appears unreliable — A reported “significant increase” shows zero shares in the feed (data inconsistent); no clear short-covering pressure signaled. (internal short-interest entry)
• Negative Sentiment: Ongoing franchise pressure and execution risk — Coverage notes that legacy multiple sclerosis (MS) franchise pressures and execution on expanding Leqembi access/commercial scale remain risks that could cap near-term upside. Article Title

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.